GeneDx Holdings Corp. Class A

XNASHealth care

Last traded price · USD

$68.90

−0.63%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:20 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $69.34
Volume: 114
Day's high: —
Day's low: —

In brief

GeneDx Holdings Corp. is a health care company listed on Nasdaq, valued at about $2.05B.
Its shares closed at $69.34 on 4 Nov 2026, down 50.3% over the past year.
From India you can buy WGS in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy GeneDx Holdings Corp. (WGS) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole WGS share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade WGS options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −3.0% (SPY −1.6%, XLV +13.5%). 3 months: −0.8% (SPY −0.4%, XLV +15.5%). 1 year: −50.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: WGS, SPY and XLV · as of 4 Nov 2026
8.7 days to cover short interest
6.0M shares were sold short at the 15 Oct 2026 settlement, 20.2% of the 29.8M shares outstanding; covering them would take 8.7 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $69.34 was 11.0% below its 50-day average ($77.89) and 2.8% below its 200-day average ($71.35). It has closed below the 200-day for 27 sessions, since 29 Sep 2026. The 50-day average crossed above the 200-day on 28 Sep 2026, 27 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
27% of the way up its 52-week range
Closed at $69.34 on 4 Nov 2026: 59.4% below the 52-week high of $170.87 (2 Dec 2025) and 115.3% above the low of $32.21 (6 May 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−3.0%

6 months+99.8%

1 year−50.3%

5 years—

Newswire

About

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Website

Notable moves

May 5, 2026
−49.20%
October 29, 2024
+49.88%
April 30, 2024
+55.18%

Newswire

About

Website

Notable moves

May 5, 2026
−49.20%
October 29, 2024
+49.88%
April 30, 2024
+55.18%

GeneDx Holdings Corp. Class A

XNASHealth care

Last traded price · USD

$68.90

−0.63%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:20 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $69.34
Volume: 114
Day's high: —
Day's low: —

In brief

GeneDx Holdings Corp. is a health care company listed on Nasdaq, valued at about $2.05B.
Its shares closed at $69.34 on 4 Nov 2026, down 50.3% over the past year.
From India you can buy WGS in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy GeneDx Holdings Corp. (WGS) shares from India?

Do I need the price of a whole WGS share to invest?

How much can I invest in US stocks in a year?

Can I trade WGS options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −3.0% (SPY −1.6%, XLV +13.5%). 3 months: −0.8% (SPY −0.4%, XLV +15.5%). 1 year: −50.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: WGS, SPY and XLV · as of 4 Nov 2026
8.7 days to cover short interest
6.0M shares were sold short at the 15 Oct 2026 settlement, 20.2% of the 29.8M shares outstanding; covering them would take 8.7 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $69.34 was 11.0% below its 50-day average ($77.89) and 2.8% below its 200-day average ($71.35). It has closed below the 200-day for 27 sessions, since 29 Sep 2026. The 50-day average crossed above the 200-day on 28 Sep 2026, 27 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
27% of the way up its 52-week range
Closed at $69.34 on 4 Nov 2026: 59.4% below the 52-week high of $170.87 (2 Dec 2025) and 115.3% above the low of $32.21 (6 May 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−3.0%

6 months+99.8%

1 year−50.3%

5 years—

Newswire

About

Website

Notable moves

May 5, 2026
−49.20%
October 29, 2024
+49.88%
April 30, 2024
+55.18%

Newswire

About

Website

Notable moves

May 5, 2026
−49.20%
October 29, 2024
+49.88%
April 30, 2024
+55.18%

GeneDx Holdings Corp. Class A

GeneDx Holdings Corp. in brief

Behind SPY and its sector fund XLV over 1 year

8.7 days to cover short interest

Below its 50- and 200-day averages

27% of the way up its 52-week range

GeneDx Holdings Corp. Class A

GeneDx Holdings Corp. in brief

Behind SPY and its sector fund XLV over 1 year

8.7 days to cover short interest

Below its 50- and 200-day averages

27% of the way up its 52-week range